DNA Sequencing Market to Hit US$ 51.31 Billion by 2034 at 14.9% CAGR, Led by North America's 44% Share and Key Players Illumina, Thermo Fisher & Roche

The Global DNA Sequencing Market reached US$ 12.79 billion in 2024 and is projected to grow to US$ 51.31 billion by 2034, registering a CAGR of 14.9% during 2024-2034. DNA sequencing technologies, including next-generation sequencing, long-read platforms, consumables, software, and sequencing services,are being rapidly adopted across clinical diagnostics, oncology, reproductive health, genomics research, and biotechnology. Widespread use in cancer profiling, rare disease detection, infectious disease monitoring, and population genomics is significantly accelerating market expansion.

Growth is driven by continuous improvements in sequencing accuracy and speed, decreasing per-sample costs, rising demand for precision medicine, and expanding government and private-sector investments in genomic research. North America currently holds the largest market share, supported by strong research infrastructure and advanced healthcare systems, while Asia-Pacific is emerging as one of the fastest-growing regions due to increasing genomics initiatives, expanding diagnostic capabilities, and rising healthcare funding.

Get a Free Sample PDF Of This Report (Get Higher Priority for Corporate Email ID):- https://www.datamintelligence.com/download-sample/dna-sequencing-market?sai-v

The DNA Sequencing Market is revolutionizing healthcare and research with ultra-precise genomic technologies that unlock faster diagnostics, personalized medicine, and deeper biological insights.

Key Developments

United States
✅ September 2025: U.S. genomics companies expanded development of high-throughput sequencing platforms enabling faster whole-genome sequencing at reduced cost for clinical diagnostics and research.

✅ June 2025: American healthcare institutions accelerated adoption of next-generation sequencing (NGS)-based oncology panels for early cancer detection, precision therapies, and personalized medicine.

✅ April 2025: U.S. biotech startups introduced AI-powered sequencing analytics tools to improve mutation detection accuracy and streamline clinical interpretation workflows.

Japan
✅ October 2025: Japanese biotechnology firms developed ultra-fast, compact sequencing devices optimized for point-of-care genetic testing in hospitals and decentralized labs.

✅ July 2025: Japan's pharmaceutical sector increased integration of advanced NGS platforms in drug discovery, rare disease analysis, and biomarker identification programs.

✅ March 2025: Japanese research institutes created novel nanopore and optical sequencing technologies offering enhanced read accuracy for complex genomic regions.

Mergers & Acquisitions

United States
✅ May 2025: A leading U.S. genomics solutions provider acquired a sequencing software company specializing in AI-driven genomic interpretation to enhance clinical sequencing capabilities.

Japan
✅ February 2025: A Japanese sequencing equipment manufacturer partnered with a domestic advanced materials developer to co-create next-generation microfluidic components for high-efficiency sequencing.

✅ January 2025: A Japan-based molecular diagnostics company formed a strategic alliance with a U.S. distributor to expand access to premium sequencing instruments and consumables across global markets.

Key Players
Agilent Technologies Inc. | Bio-Rad Laboratories Inc. | Danaher Corporation | Eurofins Scientific | F. Hoffmann-La Roche | Illumina Inc. | Merck KGaA | Pacific Biosciences of California Inc. | PerkinElmer Inc. | Thermo Fisher Scientific Inc.

Key Highlights

• Agilent Technologies Inc. - Holds 11.4% share of the global life sciences and analytical instruments market, driven by strong chromatography, mass spectrometry, and genomics product portfolios.

• Bio-Rad Laboratories Inc. - Accounts for 6.2% share, backed by its leadership in PCR, cell biology, and clinical diagnostics solutions.

• Danaher Corporation - Represents 17.3% share, supported by its diversified life sciences, diagnostics, and biotechnology instrumentation platforms.

• Eurofins Scientific - Maintains 5.7% share, driven by its global network of testing laboratories and strong demand for genomic, environmental, and biopharma analytical services.

• F. Hoffmann-La Roche - Holds 9.8% share, fueled by advanced molecular diagnostics, sequencing solutions, and automated testing systems.

• Illumina Inc. - Accounts for 8.6% share, recognized for dominance in next-generation sequencing (NGS) platforms and genomic analysis systems.

• Merck KGaA - Represents 7.9% share, supported by high-demand bioprocessing tools, reagents, and life science research technologies.

• Pacific Biosciences of California Inc. - Holds 3.4% share, driven by its long-read sequencing platforms used in genomics, clinical research, and precision medicine.

• PerkinElmer Inc. - Maintains 6.8% share, known for analytical instruments, life science research tools, and applied laboratory solutions.

• Thermo Fisher Scientific Inc. - Leads with 18.5% share, supported by its extensive portfolio of analytical instruments, sequencing systems, reagents, and bioscience technologies.

Purchase this report before year-end and unlock an exclusive 30% discount: https://www.datamintelligence.com/buy-now-page?report=dna-sequencing-market?sai-v(Purchase 2 or more Reports and get 50% Discount)

Market Drivers
• Growing prevalence of genetic disorders, cancer, and infectious diseases is driving strong demand for DNA sequencing technologies in clinical diagnostics.

• Rapid adoption of next-generation sequencing (NGS) due to its high accuracy, scalability, and declining cost per genome.

• Expansion of personalized medicine and targeted therapies is increasing the need for genomic profiling and precision-based treatment decisions.

• Rising investments in genomics research, biobanks, and large-scale population sequencing programs across countries.

• Growing use of sequencing in agriculture, microbiome studies, and environmental testing is expanding market applications beyond healthcare.

• Technological advancements such as long-read sequencing, nanopore technologies, and AI-driven genomic analytics are enhancing performance and speed.

Industry Developments
• Companies introduced ultra-fast NGS platforms with higher throughput and lower operational costs for clinical and research use.

• Expansion of portable sequencing devices for point-of-care, field diagnostics, and rapid pathogen detection.

• Development of AI-powered genomic interpretation tools to accelerate clinical decision-making and improve variant detection accuracy.

• Increasing collaborations between pharmaceutical companies and sequencing technology providers to support drug discovery and biomarker validation.

• Growth in single-cell sequencing technologies enabling deeper insights into cell behavior, cancer heterogeneity, and immune profiling.

• Investments in cloud-based genomic data storage and analysis platforms to manage rapidly growing sequencing datasets.

Regional Insights
• North America holds 44% share, driven by strong genomics research funding, advanced healthcare infrastructure, and widespread adoption of NGS-based clinical diagnostics.

• Europe accounts for 28% share, supported by national genome programs, rising demand for precision medicine, and strong biotechnology research hubs.

• Asia-Pacific holds 22% share, fueled by expanding genomics initiatives in China, India, and Japan, increasing cancer diagnostics, and growing biotech investments.

• Latin America represents 4% share, with growth driven by rising adoption of genetic testing and improved access to sequencing technologies.

• Middle East & Africa account for 2% share, supported by developing healthcare systems, increasing rare disease diagnostics, and emerging research activity.

Speak to Our Analyst and Get Customization in the report as per your requirements: https://www.datamintelligence.com/customize/dna-sequencing-market?sai-v
Key Segments:
➥ By Product Type
Instruments dominate the market as advanced sequencing platforms, analyzers, and automated systems enable higher throughput, improved accuracy, and rapid genomic data generation. Consumables, including reagents, flow cells, sample prep kits, and cartridges, represent a recurring revenue segment driven by frequent usage across research, clinical, and diagnostic workflows. Others include software tools, accessories, and specialized components that support workflow optimization, data processing, and system compatibility.

➥ By Sequencing Type
Next-Generation Sequencing (NGS) leads adoption due to its high efficiency, massive parallel sequencing capability, cost-effectiveness, and suitability for genomics, oncology, infectious disease analysis, and personalized therapies. Sanger sequencing remains essential for low-throughput applications, targeted validation, small DNA fragments, and sequence confirmation in clinical and research settings. Others include emerging sequencing technologies and hybrid sequencing approaches designed to enhance read accuracy, speed, and long-fragment analysis.

➥ By Application
Diagnostics represent a major segment as sequencing-enabled tools support early disease detection, genetic disorder screening, oncology testing, pathogen identification, and precision diagnostics. Personalized medicine continues to grow rapidly due to increasing use of genomic insights for treatment selection, drug response prediction, and tailored therapeutic strategies. Others include academic research, biotechnology development, pharmacogenomics, and evolutionary or microbial studies that rely on genomic sequencing for scientific advancement.

Unlock 360° Market Intelligence with DataM Subscription Services: https://www.datamintelligence.com/reports-subscription

Power your decisions with real-time competitor tracking, strategic forecasts, and global investment insights all in one place.

✅ Competitive Landscape
✅ Sustainability Impact Analysis
✅ KOL / Stakeholder Insights
✅ Unmet Needs & Positioning, Pricing & Market Access Snapshots
✅ Market Volatility & Emerging Risks Analysis
✅ Quarterly Industry Report Updated
✅ Live Market & Pricing Trends
✅ Import-Export Data Monitoring

Have a look at our Subscription Dashboard: https://www.youtube.com/watch?v=x5oEiqEqTWg

Contact Us -

Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About Us -

DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.

Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.